Stoke Therapeutics slumps on safety concern over genetic epilepsy drug data

Stoke Therapeutics

14/11/2022 17:38

** Shares of Stoke Therapeutics Inc  STOK.O  slump ~27% to
$9.10 - set for worst daily pct fall on record
    ** Stock top loser on Nasdaq Biotechnology index  .NBI 
    ** Co says its experimental drug, STK-001, shows median
reductions in seizure frequency in an early- to mid-stage study
for treating Dravet syndrome, a severe and progressive genetic
epilepsy 
    ** Brokerage BTIG cites safety issues with increased protein
in cerebrospinal fluid, a watery fluid that flows in and around
brain and spinal cord
    ** The finding could likely "slow development modestly" for
the drug, with STOK agreeing to limit dosing in two of its
extension trials - BTIG
    ** Including session's loss, stock down ~62% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))